
Mupiravir intermediate
Price | Get Latest Price | |
Package | 1kg | 25kg |
Min. Order: | 1kg |
Supply Ability: | 500kg |
Update Time: | 2025-05-08 |
Product Details
Product Name: Mupiravir intermediate | CAS No.: 917389-30-1 |
Min. Order: 1kg | Purity: 0.99 |
Supply Ability: 500kg | Release date: 2025/05/08 |
?Letermovir Intermediate (CAS 917389-30-1) | High-Performance Building Block for Antiviral API Synthesis?
?Google Search Keywords?: Letermovir Intermediate, CAS 917389-30-1, Letermovir Synthesis Material, CMV Inhibitor Intermediate, Antiviral Drug Intermediate
?? ?Product Overview?
Letermovir Intermediate (CAS 917389-30-1) is a pivotal chemical intermediate in the synthesis of ?Letermovir?, a novel antiviral agent targeting cytomegalovirus (CMV) infections, particularly in immunocompromised patients (e.g., transplant recipients). This intermediate ensures efficient, scalable production of Letermovir API while adhering to stringent pharmaceutical quality standards.
?Primary Function?: Enables high-yield, impurity-controlled synthesis of Letermovir API.
?Applications?: Antiviral drug manufacturing, CMV therapy R&D, generic drug development.
? ?Key Advantages?
? ?Ultra-High Purity?
Purity ≥99% (HPLC/LC-MS validated), minimizing synthesis byproducts and ensuring API compliance.
?? ?Process Optimization?
Reduces synthesis steps by 20-30%, enhancing cost-efficiency and scalability for commercial production.
??? ?Robust Stability?
Stable under controlled conditions (2-8°C), ideal for long-term storage and global distribution.
?? ?Regulatory Ready?
Manufactured under ?ICH Q7? and ?GMP? guidelines, compliant with USP/EP specifications for intermediates.
?? ?Applications?
?API Production?: Core precursor in Letermovir API synthesis for CMV prophylaxis and treatment.
?Generic Antiviral Drugs?: Supports cost-effective alternatives to branded CMV therapies.
?Antiviral Research?: Used to develop next-generation CMV inhibitors with improved resistance profiles.
?Clinical Trial Materials?: Critical for scaling batches in pre-clinical and Phase I-III studies.
?? ?Quality Certifications?
Rigorously tested via ?HPLC, NMR, LC-MS, and GC? (aligned with ICH/USP/EP protocols).
Comprehensive Certificate of Analysis (CoA) includes impurity profiles, spectral data, and chromatograms.
?? ?Market Trends?
The global CMV treatment market is projected to grow at ?5.8% CAGR (2024-2028)?, fueled by increasing organ transplant rates and demand for targeted antiviral therapies like Letermovir. Intermediate suppliers are pivotal in meeting API production needs, especially in regions with expanding access to post-transplant care (e.g., Asia-Pacific and North America).
?? ?Why Choose Us??
?Custom Synthesis?: Flexible purity grades (98%-99.9%) and batch sizes (grams to kilograms).
?Reliable Supply Chain?: Temperature-controlled logistics with real-time tracking and regulatory documentation.
?Technical Support?: End-to-end assistance in process optimization, impurity control, and regulatory filings.
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1KG |
VIP5Y
|
Shandong Luning Pharmaceutical Co., Ltd.
|
2024-01-24 | |
$0.00/1KG |
VIP3Y
|
Zhengzhou Anbu Chem Co.,Ltd
|
2023-06-19 | |
$0.00/1kg |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-19 |
+86-+undefined-+86 13343427080
sales@biocarchem.com